Preclinical Testing of an Adenoviral Vector based HSV-2 Vaccine

Award Information
Agency:
Department of Health and Human Services
Amount:
$600,000.00
Program:
SBIR
Contract:
1R43AI077147-01A1
Solitcitation Year:
2008
Solicitation Number:
PHS2007-2
Branch:
N/A
Award Year:
2008
Phase:
Phase I
Agency Tracking Number:
AI077147
Solicitation Topic Code:
N/A
Small Business Information
GENVEC, INC.
GENVEC, INC., 65 W WATKINS MILL RD, GAITHERSBURG, MD, 20878
Hubzone Owned:
Y
Woman Owned:
Y
Socially and Economically Disadvantaged:
Y
Duns:
806729547
Principal Investigator
 () -
Business Contact
Phone: (240) 632-5537
Email: rking@genvec.com
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): This proposal will leverage the expertise in HSV-2 and cellular immunology developed at the UW/FHCRC with the state of the art adenovirus delivery platform developed by GenVec to develop an HSV-2, adenovirus vector base d vaccine. This phase 1 SBIR application will generate and test in preclinical models initial prototypes of such a vaccine. The specific aims during phase I of the SBIR are to construct and test two adenovirus vectors each containing a HSV-2 viral antigen, UL-47 and UL-19. These antigens have been shown to cause prevalent in CD4+ and CD8+ T cell responses among humans with naturally acquired HSV-2. It is anticipated that the proposed AdHSV-2 vaccine will increase the HSV-2 specific CD8+ T cell responses to the UL-47 and UL-19 antigens in animal models. During phase II of this SBIR we plan to bring these AdHSV-2 vaccines to the IND stage. The long-term goal of this effort is to conduct clinical trials testing whether AdHSV-2 vaccines decrease acquisition of H SV-2 and/or decrease viral reactivation as measured by frequency and titer of viral shedding and lessened rate of recurrent episodes. PUBLIC HEALTH RELEVANCE: The HSV-2 epidemic has continued to spread throughout the world and seroprevalence rates have climbed to 30-50%. There is a strong association between antecedent HSV-2 infection and increased risk of HIV acquisition. Antiviral therapy to reduce transmission of HSV-2 to sexual partners is only partially successful. No effective HSV-2 vaccine is currently available. Evidence has accumulated on the importance that HSV-2 specific CD8+ T cells play in control of latency and reactivation of HSV-2 infections in humans. Concomitant with these studies of HSV-2 immunobiology has been the recent demonstra tion in humans that recombinant adenovirus vectors elicit high frequency of HIV CD8+ T cell responses. This proposal will leverage the expertise in HSV-2, and cellular immunology developed in the laboratories of Drs. L. Corey and D. Koelle with the state o f the art adenovirus delivery platform developed by GenVec to develop an HSV-2, Ad5 based vaccine.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government